Overview of Fosinopril-Reference-Cited by-同舟云学术

Overview of Fosinopril

Published:1991-01 Issue:S4 Volume:3 Page:3-11
ISSN:0114-2402
Container-title:Drug Investigation
language:en
Short-container-title:Drug Invest

Author:

Weber Michael A.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine,Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/BF03259526.pdf

Reference39 articles.

1. Anderson RJ, Duchin KL, Gore RD, et al. Once-daily fosinopril in the treatment of hypertension. Hypertension 17: 636–642, 1991

2. Brunner HR, Nussberger J, Waeber B. The present molecules of converting enzyme inhibitors. Journal of Cardiovascular Pharmacology 7 (Suppl. 1): S2–S11, 1985

3. Cirillo VJ, Till AE, Gomez HJ, et al. Effect of age on lisinopril pharmacokinetics. (Abstract). Clinical Pharmacology and Therapeutics 39: 187, 1986

4. Clementy J. Double-blind, randomised study of fosinopril versus nifedipine SR in the treatment of mild-to-moderate hypertension in elderly patients. Drug Investigation 3 (Suppl. 4): 45–53, 1991

5. Creasey WA, Brennan J, McKinstry DN, Fordtran JS. Absorption of fosinopril from various sites within the gastrointestinal tract. Acta Pharmacologica et Toxicologica 59 (Suppl. 5): 83, 1986

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A sensitive and efficient LC–MS/MS method for the bioanalysis of fosinopril diacid from human plasma and its application for a bioequivalence study in humans;Biomedical Chromatography;2021-02-02

2. Current genetic engineering strategies for the production of antihypertensive ACEI peptides;Biotechnology and Bioengineering;2020-06-04

3. FOSINOPRIL NATIONAL SURVEY: A POST‐MARKETING SURVEILLANCE STUDY OF FOSINOPRIL (STARIL^TM) IN GENERAL PRACTICE IN THE UK;International Journal of Clinical Practice;1997-09

4. Fosinopril Versus Enalapril in the Treatment of Hypertension: A Double-Blind Study in 195 Patients;Journal of Cardiovascular Pharmacology;1996-07

5. Temocapril, A Novel Angiotensin-Converting Enzyme Inhibitor with Preferential Biliary Excretion;Cardiovascular Drug Reviews;1995-03